Dr. William E. Davis
Rheumatology (Rheumatology Physician)
1514 Jefferson Hwy
New Orleans, LA 70121
Who else practices at this address →
Jefferson Parish includes primary care (18% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Louisiana State University School of Medicine in New Orleans (1983)
- Years since graduation
- 43
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 172
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1983Medical school: Louisiana State University School of Medicine in New Orleans
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
LA license MD.017251
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ochsner Medical Center Acute New Orleans, LA
- Ochsner Medical Center - Baton Rouge Baton Rouge, LA
- Slidell Memorial Hospital Slidell, LA
- Ochsner Medical Center-Hancock Bay Saint Louis, MS
- St Bernard PArish Hospital Chalmette, LA
Medical groups
- Ochsner Clinic LLC (2,864 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 172
- Services billed
- 303
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 212 | 126 |
| Established patient office or other outpatient visit, 20-29 minutes | 26 | 25 |
| New patient office or other outpatient visit, 45-59 minutes | 13 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Methotrexate (methotrexate sodium) Other prescribers in New Orleans, LA | 411 |
| Hydroxychloroquine Sulfate Other prescribers in New Orleans, LA | 329 |
| Prednisone Other prescribers in New Orleans, LA | 327 |
| Tramadol Hcl Other prescribers in New Orleans, LA | 231 |
| Leflunomide Other prescribers in New Orleans, LA | 213 |
| Celecoxib Other prescribers in New Orleans, LA | 140 |
| Gabapentin Other prescribers in New Orleans, LA | 138 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in New Orleans, LA | 113 |
| Folic Acid Other prescribers in New Orleans, LA | 82 |
| Enbrel Sureclick (etanercept) Other prescribers in New Orleans, LA | 78 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 25 payments worth $18,264 in total to this clinician.
| Amgen Inc. | $15,517 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $2,266 |
| AbbVie Inc. | $228 |
| UCB, Inc. | $129 |
| GlaxoSmithKline, LLC. | $125 |
| Compensation for services other than consulting (speaking, faculty) | $15,250 |
|---|---|
| Consulting Fee | $2,148 |
| Food and Beverage | $866 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Amgen Inc. May 7, 2025 | Compensation for services other than consulting (speaking, faculty) UPLIZNA · Inflammation/Rare Disease | $3,750 |
| Amgen Inc. May 7, 2025 | Compensation for services other than consulting (speaking, faculty) UPLIZNA · Inflammation/Rare Disease | $3,750 |
| Amgen Inc. Jul 10, 2025 | Compensation for services other than consulting (speaking, faculty) | $3,000 |
| AstraZeneca Pharmaceuticals LP Jun 3, 2025 | Consulting Fee | $2,148 |
| Amgen Inc. May 7, 2025 | Compensation for services other than consulting (speaking, faculty) UPLIZNA · Inflammation/Rare Disease | $1,500 |
| Amgen Inc. May 7, 2025 | Compensation for services other than consulting (speaking, faculty) UPLIZNA · Inflammation/Rare Disease | $1,500 |
| Amgen Inc. Feb 18, 2025 | Compensation for services other than consulting (speaking, faculty) UPLIZNA · Inflammation/Rare Disease | $1,000 |
| Amgen Inc. Apr 23, 2025 | Compensation for services other than consulting (speaking, faculty) UPLIZNA · Inflammation/Rare Disease | $750 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $74,743 in research payments for these studies, mostly to the institutions running them.
- A Multicenter,Randomized,Double blind,Placebo controlled,Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients with Systemic Sclerosis
AstraZeneca Pharmaceuticals LP - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
AbbVie Inc. · Completed · NCT03104400 - A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis
AbbVie Inc. · Completed · NCT03725202
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.